Brief: In8bio Presents Positive Data Demonstrating Durable 1-Year Complete Remission In 100% Of Evaluable Patients In Phase 1 Trial Of Inb-100

IN8bio

13/06/2024 22:54

IN8BIO, Inc.  INAB.O :
    * IN8BIO PRESENTS POSITIVE DATA DEMONSTRATING DURABLE 1-YEAR
COMPLETE REMISSION IN 100% OF EVALUABLE PATIENTS IN PHASE 1
TRIAL OF INB-100
    * IN8BIO, INC. - 100% OF TREATED LEUKEMIA PATIENTS (N=10/10)
ACHIEVED DURABLE COMPLETE REMISSION (CR) AT 1-YEAR
    * IN8BIO - DATA CONTINUE TO SHOW LONG-TERM IN VIVO
EXPANSION,
PERSISTENCE OF ALLOGENEIC GAMMA-DELTA T CELLS 365 DAYS FOLLOWING
SINGLE ADMINISTRATION
    * IN8BIO, INC. - TRIAL HAS BEEN EXPANDED TO ENROLL AN
ADDITIONAL
TEN PATIENTS AT DOSE LEVEL 2 (DL2)
    * IN8BIO, INC. - ENROLLMENT AND TREATMENT OF PATIENTS INTO
EXPANSION COHORT IS ONGOING, WITH UPDATED DATA EXPECTED IN LATE
2024 AND 2025

Source text for Eikon:  ID:nGNX5xFpbz 
Further company coverage:  INAB.O